Sanofi India Ltd (SANOFI) is currently trading at 3,181.10 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Sanofi India Limited is a leading multinational pharmaceutical company manufacturing and marketing prescription medicines in India, with manufacturing facilities in Goa and Ankleshwar and a strategic focus on diabetes, cardiovascular and CNS therapies while selling through independent distributors and a restructured consumer healthcare subsidiary post-demerger. The company reported a strong quarter driven by diabetes: Q2 domestic growth delivered about 14% quarter-on-quarter in diabetes, first half diabetes growth around 17%, overall domestic sales up while exports faced headwinds; Q2 profit before tax improved materially with margin expansion and cash balance increased by approximately 34%. Diabetes is the strategic priority with Sanofi owning Lantus, Toujeo and Soliqua, claiming leadership in basal analogs with roughly 58% value share and 61% volume share in basal analogs, and management reports a 70% growth in public sector sales through targeted expansion into state and institutional accounts. Management emphasised discipline in operating expenses, operational restructuring and a partnership model for legacy brands with Emcure and Cipla to broaden market coverage; Goa site is being positioned as a specialized manufacturing hub to offset export declines while tender opportunities and bringing back CMO volumes are part of the export strategy. Sanofi India is combining commercial execution with social and community programs: CSR initiatives (KiDS and Mobile Medical Units) are expanding via an MoU with NHM Madhya Pradesh to reach screening and treatment goals, and company investment in digital and AI patient journeys complements its public sector access push.

Over the past 52 weeks, Sanofi India Ltd has traded between a low of ₹2,758.30 and a high of ₹4,823.50. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Sanofi India Ltd has a market capitalization of approximately 7,345.76. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Sanofi India Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 20.34 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 7,345.76 Cr, Sanofi India Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Sanofi India Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Sanofi India Ltd is 20.34. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Sanofi reported Q2 2026 net sales growth of 17.8% at constant exchange rates (CER), with net sales of €11,597 million.

It disclosed an intimation confirming the publication of its unaudited financial results notice for the quarter and half-year ended June 30, 2026.

Revenue from operations for the quarter ended June 30, 2026 was ₹2,357 million (₹235.7 crore), up 7% year-on-year.

It informed exchanges about the publication and availability of its unaudited financial results for the quarter and half-year ended June 30, 2026, as a routine SEBI Regulation 30 compliance.